Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

COX-2 inhibitors and renal damage in obesity-related Type II diabetes

01.10.2003


New findings suggest altered kidney regulation of COX-2 occurs at very early stage in obesity-related diabetic nephropathy



In human diabetic patients, an excessive vasoconstrictive and pro-aggregatory thromboxane (TXA2) renal synthesis, along with a decrease in vasodilatory and anti-aggregatory prostaglandin (PGE2) synthesis, has been found to influence kidney function. Prostaglandins and thromboxane are formed by the enzymatic oxidation of arachidonic acid catalyzed by the cyclooxygenases, COX 1 and COX-2. Recently developed non-steroidal anti-inflammatory drugs (NSAIDS) are targeted to inhibit COX-2 and treat inflammation and arthritic pain. It is not known if the use of NSAIDS may be beneficial for the treatment of kidney disease; however, the upregulation of pro-inflammatory COX-2 and increased production of COX-2 derived metabolites have been implicated in diabetic nephropathy. COX-2 regulation and its association with renal damage are not known in the Obese Zucker rat. A new study tests the hypothesis that altered kidney regulation of COX-2 occurs at a very early stage in the progression of kidney disease.

A New Study


The authors of the study entitled, "Renal Microvascular COX-2 Upregulation is Associated with Kidney Damage in Zucker Obese Rats," are Aparajita Dey, Roger S. Williams, David M. Pollock, David W. Stepp and John D. Imig, all from the Vascular Biology Center, Medical College of Georgia, Augusta, GA. They are presenting their findings during the American Physiological Society (APS) (www.the-aps.org) conference, Understanding Renal and Cardiovascular Function Through Physiological Genomics. The scientific conference is being held October 1-4, 2003 at the Radisson Riverfront Hotel and Convention Center, Augusta, GA.

Background

Obesity, a major nutritional disorder in the United States, leads to the development of Type II diabetes, hypertension, atherosclerosis and chronic renal disease, most of which are interdependent factors. Diabetic nephropathy, a kidney disease that develops in as many as 20 to 40 percent of diabetics, is the leading cause of end stage renal disease (ESRD). In addition to diabetes, obesity, hypertension, hyperlipidemia and other risk factors contribute to the development and progression of kidney disease.

The Obese Zucker rat displays all the metabolic characteristics associated with Type II diabetes and hypertension, and develops extensive renal damage. Obese Zucker rats possess a mutant leptin receptor that explains their uncontrolled appetite and, consequently, results in obesity and its associated characteristics (insulin resistance, hypertension, etc.), although the mechanisms responsible for renal damage in the Obese Zucker rat remain unknown.

Methodology

Obese Zucker rats at 10-12 weeks or 20-21 weeks of age were studied. The rats were housed in separate cages and maintained in a temperature and light-controlled room. Throughout the experimental period, animals had access to standard chow and drinking water. Blood pressure was measured in the conscious state utilizing the radiotelemetry method. Blood glucose levels and body weight were measured periodically.

Protein expression of COX-1 and COX-2 in the kidney cortex, renal microvessels and glomeruli was studied. The levels of 6-keto PGF1a, PGF2a, PGE2 and TXB2 in urine were measured using enzyme immunoassays. Urinary albumin excretion, and indicator of kidney damage, was measured. Kidneys were perfusion fixed in 10% buffered formalin solution and embedded in paraffin for light microscopic evaluation.

Results

The researchers found that:
  • the Obese Zucker rats weighed 432 ± 20 g with a blood glucose of 105 ± 5 mg/dl at 10-12 weeks of age and weighed 679 ± 12 g with a blood glucose of 161 ± 13 mg/dl at 20-21 weeks of age. Blood pressure was slightly elevated in the Obese Zucker rat compared to lean rats and averaged 105 ± 5 mmHg;

  • increased COX-2 protein expression was observed in the kidney cortex and microvessels of the Obese Zucker rats at 10-12 and 20-21 weeks of age. The increase in COX-2 protein expression was associated with increases in TXB2 and decreases in PGE2 urinary excretion rates; and

  • increased urinary albumin was evident in the Obese Zucker rat at 10-12 weeks of age and averaged 7±1 mg/d. At 20-21 weeks of age renal vascular and glomerular damage progressed as assessed histologically and urinary albumin excretion increased to 117 ± 10 mg/d in the Obese Zucker rats.

Conclusions

Obesity is a major risk factor that, along with hyperglycemia and hypertension, contributes to the progression of kidney disease. Previous studies in models of Type I diabetes have suggested that COX-2 may contribute to diabetic nephropathy. In this study researchers found increases in renal COX-2 levels and changes in TXA2 and PGE2 levels in the Obese Zucker rat. The changes in TXA2 and PGE2 are similar to those found in the diabetic patient population.

Interestingly, these changes occurred in the Obese Zucker rat at pre-hyperglycemic and pre-hypertensive stages. Renal damage was minimal at 10-12 weeks of age and progressed rapidly towards kidney failure by 20-21 weeks of age. Therefore, during the development of obesity-related diabetes, alternations in COX-2 derived metabolites could contribute to the renal damage associated with this disease. Taken as a whole, these findings suggest that COX-2 inhibitors may be beneficial for the prevention of renal damage in obesity-related type II diabetes.


The American Physiological Society (APS) is one of the world’s most prestigious organizations for physiological scientists. These researchers specialize in understanding the processes and functions by which animals live, and thus ultimately underlie human health and disease. Founded in 1887 the Bethesda, MD-based Society has more than 11,000 members and publishes 3,800 articles in its 14 peer-reviewed journals each year.

EDITOR’S NOTE: Members of the press are invited to attend the conference and interview the researchers in person or by phone. Please contact Donna Krupa at (703) 527-7357 (office); (703) 967-2751 (cell) or djkrupa1@aol.com (email) for more information.

Meeting Dates: October 1-4, 2003
Radisson Riverfront Hotel and Convention Center, Augusta, GA


Donna Krupa | EurekAlert!
Further information:
http://www.faseb.org/aps/

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Multifunctional Platform for the Delivery of Gene Therapeutics

22.01.2018 | Life Sciences

The world's most powerful acoustic tractor beam could pave the way for levitating humans

22.01.2018 | Power and Electrical Engineering

Siberian scientists learned how to reduce harmful emissions from HPPs

22.01.2018 | Power and Electrical Engineering

VideoLinks